NEW YORK, December 29, 2025, 10:27 PM ET — Market closed
- Boston Scientific shares closed down 0.3% at $95.76.
- U.S. stocks ended lower in light, holiday-thinned trading.
- Focus shifts to year-end flows and Boston Scientific’s next earnings update in early February.
Boston Scientific shares closed down 0.3% at $95.76 on Monday. The stock traded between $95.53 and $96.64, with about 5.4 million shares changing hands.
The modest move still matters now because thin year-end liquidity can magnify small shifts in positioning. For large-cap healthcare names like Boston Scientific, traders are also watching whether defensive sectors can stay steady as leadership narrows in the final stretch of 2025.
Wall Street’s main indexes finished lower, with the Dow down 0.51%, the S&P 500 off 0.35% and the Nasdaq down 0.50%, according to Reuters. “In light volume trading, we’re seeing a reversal of what we saw over the last couple of days,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Reuters
Healthcare stocks ended slightly lower “with little fresh news to drive trading,” Dow Jones Newswires said. Johnson & Johnson said it closed its $3.05 billion acquisition of Halda Therapeutics and now expects a larger hit to adjusted earnings than it previously indicated. MarketScreener
Boston Scientific, a major medical-device maker, sells heart devices such as pacemakers and defibrillators and markets products like Watchman and Farapulse. Farapulse is used in pulsed field ablation (PFA) — a technique that uses electrical pulses to treat atrial fibrillation, an irregular heartbeat — a market where it competes with rivals including Johnson & Johnson and Medtronic. In October, Boston Scientific lifted its 2025 adjusted earnings per share forecast to $3.02 to $3.04 and guided to fourth-quarter adjusted EPS of 77 to 79 cents, excluding certain one-time items, Reuters reported.
Monday’s decline left the stock near the mid-$90s as investors looked past the calendar and toward the next check-in on procedure volumes and demand for its cardiovascular portfolio. With the market’s attention on rates and geopolitics, single-stock moves without a fresh catalyst can be hard to read in the final week of the year.
Before the next session, $95.50 — Monday’s low — is an immediate support level, while $96.60 marks the day’s high. Investing.com data show the stock’s 52-week range at $85.98 to $109.50, putting Monday’s close about 12.5% below the high.
The broader calendar is also shaping trading. U.S. markets will be closed on Thursday for New Year’s Day, keeping volumes in focus through the final sessions of 2025.
Boston Scientific’s next major scheduled catalyst is its quarterly results, which Nasdaq’s earnings calendar estimates for Feb. 4. Investors will look for updates on demand trends, pricing and any changes to the company’s outlook heading into 2026.
